Quotient Clinical receives MHRA Supplementary Accreditation
This is one of the highest levels of accreditation in Europe and confirms that Quotient Clinical is qualified to perform the full range Phase I trials, including First-in-Human (FIH) studies for low molecular weight chemical entities and biologics.
The MHRA voluntary accreditation scheme was introduced in April 2008 in line with recommendations from the MHRA clinical trial expert advisory group, to maximise subject safety, and provides formal guidance on the standards expected in a clinical unit conducting FIH studies.
Mark Egerton, Managing Director of Quotient Clinical comments: “Our MHRA Supplementary accreditation provides volunteers and sponsors with additional reassurance of the high standards we apply in performing clinical studies. This award acknowledges our continued commitment to quality and safety and underpins our status as one of the leading clinical units in Europe.”
With a highly skilled staff of 160 and a 100 bed capacity, Quotient Clinical offers a unique streamlined process to reduce the time from First-in-Man studies through to proof-of-concept, integrating flexible drug product manufacture into clinical trials. As a specialist in early development services, the company applies new technologies and expertise to speed the drug development process.
Quotient Clinical serves a broad range of customers from global pharmaceutical companies to small biotechs worldwide and is considered a leading provider of early phase studies in the UK.
Pharmafocus presents a round-up of developments in manufacturing, including facility updates from Genzyme, Caraco, MSD, …